# A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

> **NCT02640157** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 506 (actual)

## Conditions studied

- Chronic Hepatitis C
- Hepatitis C Virus
- Genotype 3 Hepatitis C Virus

## Interventions

- **DRUG:** ABT-493/ABT-530
- **DRUG:** Sofosbuvir
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT02640157
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-10
- **Final completion:** 2017-02
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02640157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02640157, "A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02640157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*